AG
BPMC

Aperio Group’s Blueprint Medicines BPMC Stock Holding History

Aperio Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1.13M Buy
10,098
+934
+10% +$98.4K ﹤0.01% 1533
2020
Q3 		$850K Buy
9,164
+109
+1% +$8.39K ﹤0.01% 1523
2020
Q2 		$706K Buy
9,055
+1,431
+19% +$96.8K ﹤0.01% 1586
2020
Q1 		$446K Buy
7,624
+70
+0.9% +$4.5K ﹤0.01% 1712
2019
Q4 		$606K Sell
7,554
-655
-8% -$49K ﹤0.01% 1696
2019
Q3 		$603K Buy
8,209
+624
+8% +$53.9K ﹤0.01% 1653
2019
Q2 		$716K Buy
7,585
+2,698
+55% +$223K ﹤0.01% 1587
2019
Q1 		$391K Buy
+4,887
New +$361K ﹤0.01% 1876
2018
Q2 		– Sell
-2,354
Closed -$216K – 2262
2018
Q1 		$216K Buy
+2,354
New +$203K ﹤0.01% 2108

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Aperio Group's BPMC Position: Q4 2020 in Review

Aperio Group increased its Blueprint Medicines (BPMC) stake by 10% in Q4 2020, buying an estimated $98.4K and bringing the position to 10,098 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1533.

Aperio Group first reported a position in BPMC in Q1 2018 and has held it in 9 quarters since. 279 funds tracked by Wall St. Rank hold BPMC as of Q4 2020.

  • Aperio Group held 10,098 shares of Blueprint Medicines worth $1.13M as of Q4 2020.
  • Aperio Group bought 934 Blueprint Medicines shares in Q4 2020, an estimated $98.4K.
  • Blueprint Medicines made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1533 holding.
  • Aperio Group first reported a position in Blueprint Medicines in Q1 2018 and has held it in 9 quarters since.
  • 279 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.